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Abstract
Background—To better target future immunization efforts, we assessed trends and disparities in
human papillomavirus (HPV) vaccine initiation among female adolescents in North Carolina over
3 years.
Methods—We analyzed data from a stratified random sample of 1,427 parents who, between
2008 and 2010, completed two linked telephone surveys: the Behavioral Risk Factor Surveillance
System and the Child Health Assessment and Monitoring Program surveys. Weighted analyses
examined HPV vaccine initiation for girls ages 11 to 17 years.
Results—HPV vaccine initiation increased modestly over time (2008, 34%; 2009, 41%; 2010,
44%). This upward trend was present within 11 subpopulations of girls, including those who lived
in rural areas, were of minority (non-black/non-white) race, or had not recently received a
preventive check-up. Looking at differences between groups, HPV vaccine initiation was less
common among girls who attended private versus public school, were younger, or lacked a recent
check-up. However, the latter difference narrowed over time. The low level of initiation among
girls without recent check-ups increased substantially (from 11% to 41%), whereas initiation
among girls with recent visits improved little (from 39% to 44%, Pinteraction = 0.007).
Conclusions—Although HPV vaccine initiation improved among several groups typically at
higher risk for cervical cancer, the lack of progress among girls with recent check-ups suggests
that missed opportunities for administration have hampered broader improvements.
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Impact—Achieving widespread coverage of HPV vaccine will require redoubled efforts to
vaccinate adolescents during routine care.
Introduction
Guidelines recommend administering human papillomavirus (HPV) vaccine to females ages
11 to 26 years to confer protection from several HPV-related cancers, as well as genital
warts (1, 2). Despite evidence that HPV vaccine is safe and effective (3-5), uptake remains
low in the United States. Just half (53.0%) of girls ages 13 to 17 years have initiated HPV
vaccine, and only one third (34.8%) have completed the 3-dose series as of 2011 (6). These
rates are far below the Healthy People 2020 goal of 80% completion (7) and also pale in
comparison to levels of initiation achieved in several other Western countries. For example,
HPV vaccine initiation is above 80% for 12- to 13-year-old girls in England (8) and
Australia (9).
Unfortunately, available data do not suggest that current immunization efforts in the United
States are leading to rapid improvements in HPV vaccine coverage. The annual gains in
initiation among girls ages 13 to 17 years have decreased from 12.1% (2007–2008) to 4.3%
(2010–2011, refs. 6, 10, 11). In contrast, the uptake of the 2 other adolescent vaccines
recently introduced in the United States (tetanus, diphtheria, and pertussis booster and
meningitis vaccine) has increased steadily since 2006 (6, 10). Without a concerted effort to
identify and address the unique challenge of HPV vaccination in the U.S. context, coverage
levels may remain far short of national goals.
To better understand the trajectory of HPV vaccine uptake, we sought to characterize
changes in HPV vaccination among adolescent girls in North Carolina over a 3-year period.
Our analyses focused on variables identified in previous studies as correlates of HPV
vaccination, including daughter’s age, daughter and parent healthcare utilization, and
urbanicity (12-15). We aimed (i) to assess trends in HPV vaccine initiation among
subgroups to determine who is and is not improving, (ii) to identify correlates of initiation
across all 3 years to understand differences and disparities in initiation, and (iii) to assess
how these correlates have changed over time. We use the term difference to refer to
correlates related to healthcare access factors (e.g., having a recent preventive check-up) and
disparity when describing correlates tied to socio-demographic factors (e.g., race), after the
definition offered by the Institute of Medicine (16), whereas we use correlate when
generally discussing both differences and disparities. By investigating trends in HPV
vaccination in both absolute and relative terms, this study aims to guide efforts to eliminate
disparities in HPV vaccination uptake while at the same time raising overall coverage levels.
Materials and Methods
Study design
This study used data collected over 3 years (2008–2010) from North Carolina residents via
the Behavioral Risk Factor Surveillance System (BRFSS) and the Child Health Assessment
and Monitoring Program (CHAMP) surveys. BRFSS monitors health-related behaviors with
an annual telephone survey of a nationally representative sample of noninstitutionalized
adults (17). Using a subset of BRFSS respondents, CHAMP is a follow-up survey that
measures the health characteristics of children younger than 18 years via parental report
(18). In North Carolina, the State Center for Health Statistics Survey Center conducts
BRFSS and CHAMP using random digit dialing and a computer-assisted telephone
interviewing system. The Survey Center uses disproportionate stratified random sampling
(18).
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During the BRFSS surveys, interviewers gathered identifying information about a randomly
selected child in the household (e.g., the child’s birth month, birth year, and sex) and
scheduled an appointment to call back about 2 weeks later to complete the CHAMP survey
with the person most knowledgeable about the child’s health (18). A unique identifier linked
CHAMP and BRFSS responses to allow use of caregiver data from the BRFSS survey. Our
analyses of the 2008–2010 data included only girls because assessment of boys’ HPV
vaccination status did not begin until 2010, a year after the vaccine received approval for use
in boys (19).
Of 7,366 caregivers who participated in the CHAMP survey in 2008–2010 (Fig. 1), 1,473
caregivers completed the HPV vaccine section of the survey about a female child age 11
through 17 years. A total of 36 of these caregivers were excluded from the study sample
because they either declined to answer HPV vaccine questions or did not know if the index
child had received the vaccine. The final analytic sample consisted of 1,437 caregivers.
Most of these caregivers were the same respondents who completed the initial BRFSS
surveys (79%). Because most caregivers (94% each year) reported being parents of the
index children, we refer to them as parents and the female children as daughters. Among the
original BRFSS respondents who were different from the CHAMP respondents, 95% were
also parents to the index child. An Institutional Review Board at the University of North
Carolina (Chapel Hill, NC) determined that this study did not require review.
Measures
The CHAMP survey assessed HPV vaccine initiation, the main study outcome, with the
question, “Has (child’s name) had any shots of the HPV vaccine?” The survey collected data
on HPV vaccine initiation rather than series completion because population-level adoption
of the vaccine remains in an early stage in the Unites States, making initiation a more
appropriate outcome to study (20). Furthermore, while clinical trials have shown that
completing the vaccine series confers protection from HPV infections and associated
cervical dysplasia (1, 4), accumulating data suggest that fewer than 3 doses may provide
substantial health benefits (1, 3, 4). Unless otherwise noted, we use initiation and coverage
to refer to having received at least one dose of HPV vaccine.
The CHAMP survey collected data on daughter’s age, race and ethnicity (non-Hispanic
white, non-Hispanic black, or other), and school type (attended public school vs. private or
home school). Healthcare-related measures included whether the daughter had health
insurance (private, public, or no insurance), had a regular healthcare provider, or had a
preventive check-up in the last 12 months. The CHAMP survey also assessed the highest
education level completed by anyone in the household, as well as location of household
residence, which we later classified as either “urban” (in a metropolitan statistical area) or
“rural” (outside of a metropolitan statistical area; ref. 21). The BRFSS survey gathered
information about parents’ demographic characteristics and whether they had received the
influenza vaccine (either shot or spray) in the last year.
Data analysis
To explore trends, we calculated the proportion of adolescents in each subgroup (e.g., non-
Hispanic whites) who initiated HPV vaccination for each study year. For each subgroup, we
then used logistic regression to assess changes in HPV vaccine initiation over the 3-year
period.
Next, we identified correlates of HPV vaccine initiation and explored how those correlates
changed over time. To maximize the power of our analysis, we pooled data from all 3 years.
We then used logistic regression to identify bivariate correlates of HPV vaccine initiation
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and entered statistically significant (P < 0.05) correlates into a multi-variate model. To
assess how correlates changed over time, we tested the interaction between each statistically
significant multivariate correlate with year. We then used adjusted Wald tests to derive an
overall P value for the interaction term for all levels of the variables of interest. Finally, we
conducted a sensitivity analysis that excluded cases in which different respondents provided
BRFSS and CHAMP data. Because this analysis yielded the same pattern of findings as the
primary analysis, we report on the analysis of the full sample only.
We applied sampling weights to percentages and tests of association to account for the
complex survey design (18); frequencies were not weighted. Analyses used Stata version 12
with 2-tailed tests and a critical α of 0.05.
Results
Demographic and healthcare characteristics
Most parents reported that their daughters were non-Hispanic white (64%) or non-Hispanic
black (21%; Table 1). A majority of daughters had private (66%) or public (24%) health
insurance, had a regular healthcare provider (82%), and had received a preventive check-up
in the previous 12 months (80%). Most parents were 40 years old or older (71%) and female
(86%). Two-thirds of parents (66%) had not received seasonal flu vaccine in the year before
the interview. Most households included a person with at least some college education
(79%) and were located in an urban area (74%). Demographic, healthcare, and household
characteristics were similar across years on all variables except that the sample included
more female parents over time.
Trends in HPV vaccine initiation by subgroup
In the study population as a whole, HPV vaccine initiation increased over time (2008, 34%;
2009, 41%; 2010, 44%). Stratified analyses identified 11 subgroups of daughters who
experienced statistically significant increases in initiation, including daughters who were
ages 13–15 (P = 0.039), whose race was non-white or non-black (P = 0.048), or who
attended public school (P = 0.013; Table 2). With respect to healthcare access and
utilization, initiation also improved among girls with a regular healthcare provider (P =
0.048) or without a recent preventive check-up (P = 0.001). In terms of parental
characteristics, HPV vaccine initiation increased among girls of respondents who were
female (P = 0.035), married (P = 0.008), or who had not received flu vaccine in the previous
year (P = 0.009). Initiation also increased among daughters who lived in households with
higher annual incomes (P = 0.007), with higher levels of education (P = 0.012), or located in
rural areas (P = 0.011). In most other subgroups, HPV vaccine initiation increased over time
without achieving statistical significance. By 2010, no subgroup’s rate of initiation was
greater than 57%, and most groups had initiation rates between 40% and 50%.
Overall correlates of HPV vaccine initiation
In analyses of correlates in the pooled sample, more older daughters (ages 13–15 and 16–17)
than younger daughters (ages 11–12) had initiated HPV vaccination, resulting in ORs of
2.02 [95% confidence interval (CI), 1.34–3.04] and 3.71 (95% CI, 2.42–5.69), respectively
(Table 3). Differences in initiation included higher initiation among girls with a recent
preventive check-up (OR, 2.09; 95% CI, 1.37–3.20) and for those whose parents had
recently received flu vaccine (OR, 1.74; 95% CI, 1.29–2.35). Initiation was lower for girls
attending private or home school rather than public school (OR, 0.48; 95% CI, 0.30–0.78).
Although urbanicity was correlated with HPV vaccine initiation in bivariate analysis, this
variable did not retain statistical significance in the multivariate model. We did not observe
statistically significant disparities by other participant characteristics (e.g., child’s race/
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ethnicity) or other differences related to healthcare utilization (e.g., type of health
insurance).
Changes in correlates over time
Our analysis of each correlate’s interaction with time indicated that the effect of having a
recent preventive check-up changed over the study period (Pinteraction = 0.007). Daughters
without recent check-ups had a low level of initial coverage that increased substantially over
time (from 11% to 41%), whereas initiation among girls with check-ups improved little
(from 39% to 44%; Fig. 2). Probing this interaction, we found that the OR for initiation
among those with a recent check-up compared with those without decreased from 5.41 (95%
CI, 2.47–11.88) in 2008 to 2.57 (95% CI, 1.26–5.24) in 2009 to 1.16 (95% CI, 0.60–2.25) in
2010. Analyses did not find interactions with time for other correlates identified as
statistically significant: child’s age, parent’s use of flu vaccine, or school type.
Discussion
Our findings indicate that between 2008 and 2010, HPV vaccine initiation increased
modestly among adolescent girls in North Carolina. Vaccine initiation improved among
some subpopulations of girls, including several groups with low levels of initiation in 2008
(12-15). Although we found that HPV vaccine initiation correlated with factors such as
child’s age and receipt of a recent preventive checkup, the latter difference narrowed over
time. Furthermore, unlike an analysis of 2008 CHAMP data (14), when we pooled CHAMP
data from 2008 to 2010, we did not find any previously reported disparities, such as higher
initiation for girls living in urban versus rural areas.
Although important, the improvements in HPV vaccine initiation were moderate to small
and were isolated to pockets of the population. For many subgroups of girls, coverage did
not improve substantially. By 2010, most groups had initiation levels between 40% and
50%, but not one achieved 80% initiation, and most fell far short. Although we did not
assess series completion, it is likely lower still, suggesting that the Healthy People 2020 (7)
goal of 80% series completion is still quite far from reach.
The relationship between HPV vaccine initiation and the use of preventive services best
illustrates the limitations of the improvements we observed. In the pooled sample, girls were
more likely to have received one or more doses of HPV vaccine if they or their parents
received other preventive healthcare services (i.e., preventive check-ups for daughters and
flu vaccine for parents). Yet the overall improvements in uptake over time were largely
driven by daughters whose families did not receive such services. For instance, daughters
with recent preventive check-ups had relatively stable levels of initiation (from 39% in 2008
to 44% in 2010), whereas initiation among daughters without check-ups improved
considerably (from 11% in 2008 to 41% in 2010). This finding suggests that although their
level of initiation was low initially, many girls from families who had not received recent
preventive care did eventually come into contact with the healthcare system and receive the
attendant benefits. Ultimately, however, this group constituted a minority of girls in the
sample (20%), limiting the population-level benefit of this trend.
The flat vaccination rate among girls who had received preventive check-ups could reflect
missed opportunities to administer HPV vaccine. Many studies have found such missed
opportunities to be common among adolescents seeking preventive care (14, 22-24), but
providers can reduce missed opportunities (25-28). Provider recommendation often strongly
correlates with whether an adolescent receives HPV vaccine (13, 29-31), although the causal
direction of this relationship is often unclear. Patients need a provider to receive HPV
vaccine, but they may initiate the process by requesting vaccination and then receiving a
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doctor’s advice. This study did not collect data on whether girls received recommendations
for HPV vaccine during their preventive visits, but future research should investigate
patient, provider, and parent behaviors during these check-ups.
Previous research suggests that HPV vaccine will offer the most protection if administered
before sexual debut (1, 32, 33), and as a result, is more cost-effective if given to younger
adolescents (33, 34). In our study, as in others (13, 14), younger girls (ages 11–12) were less
likely than older girls (ages 13–17) to have initiated the vaccine. Targeting younger
adolescents, in keeping with national guidelines, will be important for maximizing the
efficacy and cost-effectiveness of HPV vaccination. Across several studies (14, 15, 35),
including this one, the initiation of HPV vaccine did not differ by race. Given the higher
incidence of cervical cancer among non-Hispanic black versus non-Hispanic white women
(36, 37), equivalent vaccination rates may help to reduce racial disparities related to cervical
cancer. However, higher rates of vaccination for all races, but particularly for Hispanics and
non-Hispanic blacks, could be even more effective in preventing cervical cancer and
reducing the observed disparities in mortality associated with the disease (1, 11, 36, 37).
The limitations of our study include a trend design that did not permit us to interview the
same respondents over time, limiting causal inference. Although we ascertained HPV
vaccine initiation by parent’s self-report, a high percentage of parents can accurately recall
HPV vaccination status (31). In some cases, a different person answered the BRFSS and
CHAMP surveys. Although we used survey weights to account for differential response
rates, survey participation was limited to parents with landline telephones, and therefore, our
results may be less generalizable to populations with less access to land line phones, who are
more likely to be low income, rural, and of minority race/ethnicity (18).
HPV vaccination could lead to lower incidence of genital warts and several types of cancer.
However, HPV vaccine uptake is not as high as other adolescent vaccines (10, 11). From
2008 to 2010, most of the subgroups among a statewide sample of North Carolina female
adolescents and their parents moved toward a middling level of vaccine uptake. Because the
majority of girls attended preventive check-ups without receiving the vaccine, reducing
missed opportunities to vaccinate at these visits could help to increase HPV vaccine
coverage in the United States. Future research should investigate interventions aimed at
increasing HPV vaccination during these preventive check-ups, especially among younger
adolescents. It is also important to continue to monitor how correlates of HPV vaccine
uptake may be changing over time.
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Flow diagram of parents’ participation in the 2008–2010 North Carolina CHAMP surveys.
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Effect of having had a preventive check-up in the last 12 months among girls ages 11–17,
2008–2010 North Carolina CHAMP surveys.
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Table 1
.Demographic characteristics of 11- to 17-year-old daughters and their parents who participated in the 2008–









Total 554 (100) 491 (100) 392 (100) 1,437 (100)
Daughter characteristics
Age, y
 11–12 135 (29) 115 (27) 100 (29) 350 (29)
 13–15 235 (39) 202 (42) 172 (44) 609 (41)
 16–17 184 (32) 174 (31) 120 (27) 478 (30)
Race/ethnicity
 Non-Hispanic white 400 (67) 359 (60) 289 (67) 1,048 (64)
 Non-Hispanic black 82 (21) 65 (22) 58 (20) 205 (21)
 Other 72 (12) 67 (18) 45 (13) 184 (15)
School typea
 Public 487 (88) 429 (86) 351 (90) 1,267 (88)
 Private/home schooled 63 (12) 61 (14) 41 (10) 165 (12)
Healthcare coverage
 No insurance 32 (5) 31 (6) 27 (7) 90 (6)
 Public insurance 109 (21) 105 (27) 86 (24) 300 (24)
 Private insurance 384 (69) 336 (63) 268 (65) 988 (66)
 Not reported 29 (6) 19(4) 11 (4) 59 (5)
Regular healthcare provider
 No or do not know (n = 4) 80 (14) 106 (22) 65 (17) 251 (18)
 Yes 474 (86) 385 (78) 327 (89) 1,186 (82)
Preventive check-up in last 12 mo
 No or do not know (n = 7) 104 (18) 103 (21) 75 (20) 282 (20)
 Yes 450 (82) 388 (79) 317 (80) 1,155 (80)
Parent characteristics b
Age, y
 ≤39 138 (30) 123 (31) 88 (86) 349 (29)
 40–49 272 (49) 234 (46) 203 (52) 709 (79)
 ≥50 144 (21) 134 (23) 101 (22) 379 (22)
Sex
 Female 462 (83) 403 (84) 346 (90) 1,211 (86)
 Male 92 (17) 85 (16) 46 (10) 223 (14)
Marital status
 Married/member of unmarried couple 421 (76) 363 (72) 291 (75) 1,075 (74)
 Other (divorced, widowed,
  separated, never married) 133 (24) 128 (28) 101 (26) 362 (26)
Employment status
 Employed for wages/self-employed 404 (69) 344 (67) 274 (68) 1,022 (68)






















 Other (unemployed, homemaker,
  student, retired, unable to work) 150 (31) 147 (33) 118 (32) 415 (32)
Flu vaccine in the past y
 No or do not know (n = 9) 354 (63) 328 (70) 243 (66) 925 (66)
 Yes 200 (37) 163 (30) 149 (34) 512 (34)
Household characteristics
Annual household income
 <$50,000 213 (37) 199 (45) 136 (37) 548 (40)
 ≥$50,000 302 (55) 252 (49) 216 (54) 770 (52)
 Not reported 39 (8) 40 (7) 40 (10) 119 (8)
Highest education level in household
 High school or less 111 (20) 108 (23) 70 (18) 289 (21)
 Some college or more 443 (80) 383 (77) 322 (82) 1,148 (79)
Urbanicity
 Rural 170 (29) 124 (25) 93 (24) 387 (26)
 Urban 384 (71) 367 (75) 299 (76) 1,050 (74)
NOTE: The percentages reflect weighted data to account for complex survey design.
a
Excludes parents who did not know their daughters' school type (n = 2 in 2008) or whose daughters were not in school (n = 2 in 2008; n = 1 in
2009). Because of the small number of parents reporting their daughters were home schooled (n = 18 in 2008; n = 19 in 2009; n = 13 in 2010),
analyses combined data from private- and home-schooled daughters.
b
Most caregivers (94%) reported being parents of the index children. Among the original BRFSS respondents who did not complete the CHAMP
survey, 95% were also parents to the index children.













Moss et al. Page 13
Table 2







% (95% CI) P
Daughter characteristics
Age, y
 11–12 24 (16–34) 22 (13–36) 28 (18–42) 0.518
 13–15 33 (26–41) 40 (31–49) 46 (37–55) 0.039
 16–17 45 (36–54) 59 (49–69) 57 (45–68) 0.104
Race/ethnicity
 Non-Hispanic white 35 (29–41) 42 (35–49) 43 (36–50) 0.084
 Non-Hispanic black 35 (24–48) 48 (33–63) 40 (27–55) 0.601
 Other 30 (17–47) 30 (18–45) 54 (36–72) 0.048
School type
 Public 35 (30–41) 43 (37–50) 46 (40–53) 0.013
 Private/home schooled 26 (16–38) 28 (16–43) 22 (10–39) 0.693
Healthcare coverage
 No insurance 18 (6–43) 51 (28–73) 41 (19–66) 0.182
 Public insurance 37 (27–50) 48 (35–61) 50 (37–62) 0.191
 Private insurance 34 (29–40) 37 (31–44) 42 (35–50) 0.094
 Not reported 37 (17–64) 40 (13–74) 38 (9–78) 0.979
Regular healthcare provider
 No/do not know 19 (11–30) 59 (46–70) 34(21–49) 0.174
 Yes 37 (31–43) 36 (30–43) 46 (39–53) 0.048
Preventive check-up in last 12 mo
 No/do not know 11 (6–19) 24 (14–39) 41 (27–56) 0.001
 Yes 39 (34–45) 45 (39–52) 44 (38–51) 0.269
Parent characteristics
Age, y
 ≤39 31 (22–42) 41 (30–53) 47 (35–61) 0.054
 40–49 34 (27–42) 40 (32–49) 42 (34–51) 0.165
 ≥50 38 (29–48) 43 (33–55) 44 (32–56) 0.506
Sex
 Female 34 (29–39) 40 (33–46) 43 (37–50) 0.035
 Male 37 (25–49) 47 (33–62) 51 (34–67) 0.159
Marital status
 Married/member of unmarried couple 33 (27–39) 39 (32–46) 45 (38–52) 0.008
 Other (divorced, widowed, separated,
  never married) 40 (30–50) 48 (36–60) 40 (29–53) 0.973
Employment status
 Employed for wages/self-employed 38 (32–44) 40 (33–48) 47 (40–55) 0.053
 Other (unemployed, homemaker,
  student, retired, unable to work) 27 (18–37) 43 (32–54) 37 (27–48) 0.167



















% (95% CI) P
Flu vaccine in past y
 No/do not know 27 (22–33) 37 (30–45) 40 (33–48) 0.009
 Yes 47 (38–56) 50 (40–61) 51 (41–61) 0.532
Household characteristics
Annual household income
 <$50,000 34 (26–43) 42 (33–52) 38 (29–49) 0.541
 ≥$50,000 34 (27–41) 41 (33–49) 49 (40–57) 0.007
 Not reported 37 (21–58) 36 (17–61) 37 (20–58) 0.982
Highest education level in household
 High school or less 38 (26–51) 42 (29–56) 40 (27–55) 0.809
 Some college or more 33 (28–39) 41 (34–48) 45 (38–52) 0.012
Urbanicity
 Rural 22 (16–29) 39 (27–53) 41 (28–55) 0.011
 Urban 39 (33–46) 42 (35–49) 45 (28–52) 0.256
NOTE: P values are from logistic regression. All analyses used weighted data to account for complex survey design.
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Table 3
Correlates of HPV vaccine initiation among girls ages 11–17, 2008–2010 North Carolina CHAMP surveys
No. vaccinated/







 2008 194/554 34 Ref Ref
 2009 205/491 41 1.34 (0.96–1.87) 1.46 (1.04–2.06)a
 2010 174/392 44 1.50 (1.07–2.09)a 1.62 (1.13–2.32)a
Daughter characteristics
Age, y
 11–12 85/350 25 Ref Ref
 13–15 247/609 40 2.00 (1.36–2.95)b 2.02 (1.34–3.04)b
 16–17 241/478 54 3.54 (2.37–5.28)b 3.71 (2.42–5.69)b
Race/ethnicity
 Non-Hispanic white 425/1,048 40 Ref
 Non-Hispanic black 83/205 41 1.06 (0.73–1.55)
 Other 65/184 37 0.89 (0.57–1.36)
School type
 Public 523/1,267 42 Ref Ref
 Private/home schooled 47/165 25 0.47 (0.30–0.75)a 0.48 (0.30–0.78)a
Healthcare coverage
 No insurance 24/90 38 Ref
 Public insurance 136/300 46 1.38 (0.71–2.69)
 Private insurance 392/988 38 1.01 (0.54–1.87)
 Not reported 21/59 38 1.01 (0.38–2.67)
Regular healthcare provider
 No/do not know 90/251 41 Ref
 Yes 483/1,186 40 0.96 (0.66–1.38)
Preventive check-up in last 12 mo
 No/do not know 59/282 26 Ref Ref
 Yes 514/1,155 43 2.20 (1.46–3.31)b 2.09 (1.37–3.20)b
Parent characteristics
Age, y
 ≤39 131/349 40 Ref
 40–49 276–709 39 0.96 (0.68–1.36)
 ≥50 166/379 42 1.09 (0.74–1.61)
Sex
 Female 484/1,211 39 Ref
 Male 88/223 44 1.23 (0.84–1.80)
Marital status
 Married/member of unmarried couple 414/1,075 39 Ref
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No. vaccinated/





 Other (divorced, widowed, separated, never married) 159/362 43 1.20 (0.87–1.65)
Employment status
 Employed for wages/self-employed 418/1,022 42 Ref
 Other (unemployed, homemaker,
  student, retired, unable to work) 155/415 36 0.78 (0.57–1.06)
Flu vaccine in past y
 No/do not know 323/925 35 Ref Ref
 Yes 250/512 49 1.80 (1.35–2.40)b 1.74 (1.29–2.35)b
Household characteristics
Annual household income
 <$50,000 216/548 39 Ref
 ≥$50,000 315/770 41 1.10 (0.82–1.48)
 Not reported 42/119 37 0.93 (0.54–1.61)
Highest education level in household
 High school or less 117/289 40 Ref
 Some college or more 456/1,148 40 0.98 (0.69–1.40)
Urbanicity
 Rural 126/387 33 Ref Ref
 Urban 447/1,050 42 1.44 (1.03–2.02)a 1.34 (0.92–1.94)
NOTE: Models include data from all 3 years. Multivariate models include correlates that were statistically significant predictors of HPV vaccine
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